0 Items
Select Page

Usutu Virus

The first human case of Usutu viral infection was identified in the Central African Republic in 1981. The first human cases to be documented in Europe, were in Italy in 2009. These European cases were also the first to exhibit neurological manifestation of the disease, as the only two previous cases in Africa exhibited fever, rash, and jaundice. This relatively unknown and emerging zoonotic virus highlights the importance of vector-borne disease surveillance for human health.

At The Native Antigen Company, we have developed recombinant Usutu NS1 proteins to support research into the disease and development of specific immunoassays.

Usutu Virus Background

Usutu virus (USUV) is an enveloped, positive-sense, single-stranded RNA virus that belongs to the genus Flavivirus. USUV is a member of the Japanese encephalitis sero-complex of the family Flaviridae and is related to West Nile virus. The Usutu virus is maintained in a cycle between birds, which are regarded as the primary reservoir and amplification host, in addition to ornithophilic mosquitoes. USUV has also been reported to infect humans, horses and bats, which act as incidental hosts (Ashraf, U. et al). Usutu virus is recognised as an emerging pathogen and has recently been isolated from the mosquito species, C. pipiens, raising concerns that the mosquito species may act as a bridge vector, enabling transmission of USUV to mammals (Pauli, G et al).

USUV was first identified in South Africa in 1959, but later emerged in Austria in 2001, spreading throughout Europe and the Asian continent to infect a wide variety of bird species. In Europe, circulating USUV causes severe neurological symptoms in birds and is responsible for significant numbers of deaths in bird populations, including blackbirds and great grey owls. Although USUV is recognised as an emerging pathogen, little is known about USUV pathogenesis in humans. Cases of human USUV infection are uncommon but significant neurological disorders, such as encephalitis and meningoencephalitis have been reported in immunocompromised and immunocompetent patients infected with USUV (Salinas, S. et al).

References

  1. Ashraf, U et al (2015). Usutu Virus: An Emerging Flavivirus in Europe. Viruses. 7: 219–238.
  2. Pauli, G et al (2014). Usutu Virus. Transfus. Med. Hemother. 41: 73–82.
  3. Salinas, S et al (2017). Deleterious effect of Usutu virus on human neural cells. PLoS Negl. Trop Dis. 11: e0005913.

Usutu Antigens

The Native Antigen Company prepare recombinant Usutu virus NS1 protein in a proprietary mammalian cell expression system, to generate highly pure NS1 protein in its glycosylated and predominantly hexameric form.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 10 =

Live Customer Feedback

Join our mailing list

* indicates required